Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma (MREO) Cost of Revenue (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Cost of Revenue for 2 consecutive years, with $1000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cost of Revenue changed N/A to $1000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $101000.0, a 137.0% increase, with the full-year FY2023 number at $2.6 million, up 124.61% from a year prior.
  • Cost of Revenue was $1000.0 for Q3 2025 at Mereo BioPharma, down from $100000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $2.7 million in Q2 2023 to a low of -$273000.0 in Q4 2023.